EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Reimbursement of Lung Cancer in Turkey: A 10‐Year Single Center Study

Kerem Ensarioğlu iD, Berna Akıncı Özyürek, Metin Dinçer iD, Hızır Alı Gümüşler

Cancer Medicine · 2025

DOI: 10.1002/cam4.71014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Kerem Ensarioğlu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Faculty of Health Sciences, Ankara Ataturk Sanatoryum Training and Research Hospital, Ankara, Turkey. Hauptthemen laut MEDLINE: Lung Neoplasms, Health Expenditures. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective and Background Lung cancer is the most common carcinoma reported worldwide. The burden of lung carcinoma on healthcare has been reported in many countries, while a real‐life report within Turkey has yet to be published. This study aims to present the available results from a tertiary center specializing in pulmonology.

Methods

The study's population consisted of 199.112 patient admissions, which were reimbursed under the national healthcare system. After exclusion criteria, 4.991 patients were evaluated in the study. The patient's demographic data, malignancy types, diagnostic methods for lung carcinoma type and staging, and treatment modalities were recorded.

Results

The average healthcare expenditure during the treatment duration was 4289.4 (± 3739.4) USD, and the median was 3219.9 USD. The average expenditure was higher for male patients (3260 to 2977 USD, p = 0.003). Survivors had an overall lower healthcare expenditure than the non‐survivor group (2865 to 4230 USD). Patients with locally advanced disease classification also had a higher expenditure on other stages ( p < 0.001). This was not present in SCLC, as those diagnosed with SCLC had the most expenditure at the limited stage ( p < 0.001). Carcinoid tumors had the least expenditure compared to other subtypes at limited and advanced stages ( p < 0.001). SCLC had the highest expenditure requirement at the limited stage ( p < 0.001). At the locally advanced stage, large cell carcinoma, SCC, and adenocarcinoma were the subtypes requiring the highest expenditure ( p < 0.001).

Conclusion

The parameters affecting overall cost were age, gender, stage, and malignancy subtype. The healthcare expenditure was also affected by the difficulty of diagnosis, with the non‐diagnostic patient group having an overall higher cost. A longer duration of hospitalization and treatment given on an inpatient basis also contributed to a higher cost of care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsHealth ExpendituresHumansMaleTurkeyFemaleMiddle AgedAgedAdultNeoplasm StagingAged, 80 and overRetrospective Studies

Stichwörter der Autor:innen

carcinomahealth care costshealth expenditureslung

Autor:innen und Institutionen

  • Department of Pulmonary Medicine, Faculty of Health Sciences, Ankara Ataturk Sanatoryum Training and Research Hospital, Ankara, Turkey.
  • Department of Health Management, Faculty of Health Sciences, Ankara Yıldırım Beyazıt University, Ankara, Turkey.
  • Department of Invoice, Ankara Ataturk Sanatoryum Training and Research Hospital, Ankara, Turkey.

ORCID-Profile: Kerem Ensarioğlu, Metin Dinçer

Zitieren

APA

Ensarioğlu, K., Özyürek, B. A., Dinçer, M., & Gümüşler, H. A. (2025). Reimbursement of Lung Cancer in Turkey: A 10‐Year Single Center Study. Cancer Medicine. https://doi.org/10.1002/cam4.71014

Vancouver

Ensarioğlu K, Özyürek BA, Dinçer M, Gümüşler HA. Reimbursement of Lung Cancer in Turkey: A 10‐Year Single Center Study. Cancer Medicine. 2025. doi:10.1002/cam4.71014

BibTeX
@article{Ensariolu2025,
  author = {Ensarioğlu, Kerem and Özyürek, Berna Akıncı and Dinçer, Metin and Gümüşler, Hızır Alı},
  title = {Reimbursement of Lung Cancer in Turkey: A 10‐Year Single Center Study},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.71014}
}
Kostenlos starten →